NASDAQ:MRVI Maravai LifeSciences (MRVI) Stock Price, News & Analysis $6.57 0.00 (0.00%) Closing price 07/31/2026 04:00 PM EasternExtended Trading$6.57 0.00 (0.00%) As of 07/31/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Maravai LifeSciences Stock (NASDAQ:MRVI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Maravai LifeSciences alerts:Sign Up Key Stats Today's Range$6.45▼$6.7750-Day Range$4.37▼$7.2452-Week Range$1.99▼$7.44Volume1.09 million shsAverage Volume2.81 million shsMarket Capitalization$1.70 billionP/E RatioN/ADividend YieldN/APrice Target$5.50Consensus RatingHold Company Overview Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry. Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows. The company’s TriLink® division supplies custom nucleic acids and enzymatic reagents for RNA and DNA synthesis, while its SeraCode™ and ExoScale™ offerings provide specialized tools for protein quantification and extracellular vesicle analysis. Maravai also offers contract development and manufacturing services to support scale-up and commercialization efforts for novel biologic candidates. Founded in 2015 and headquartered in San Diego, California, Maravai has grown through strategic acquisitions and organic innovation to serve clients in North America, Europe and Asia. The company partners with leading pharmaceutical and biotechnology organizations to advance vaccine programs, cell and gene therapies and precision diagnostics. Under the leadership of President and Chief Executive Officer Brent P. Saunders, Maravai continues to invest in research and development, expanding its global manufacturing footprint and strengthening its position in high-growth markets for advanced therapies.AI Generated. May Contain Errors. Read More Maravai LifeSciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks30th Percentile Overall ScoreMRVI MarketRank™: Maravai LifeSciences scored higher than 30% of companies evaluated by MarketBeat, and ranked 758th out of 894 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.9 / 5Analyst RatingHold Consensus RatingMaravai LifeSciences has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 2 sell ratings.Downside RiskMaravai LifeSciences has a consensus price target of $5.50, representing about 16.3% downside from its current price of $6.57.Amount of Analyst CoverageMaravai LifeSciences has only been the subject of 4 research reports in the past 90 days.Read more about Maravai LifeSciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Maravai LifeSciences are expected to grow in the coming year, from ($0.20) to ($0.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Maravai LifeSciences is -9.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Maravai LifeSciences is -9.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMaravai LifeSciences has a P/B Ratio of 4.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Maravai LifeSciences' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.68% of the float of Maravai LifeSciences has been sold short.Short Interest Ratio / Days to CoverMaravai LifeSciences has a short interest ratio ("days to cover") of 2.98, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Maravai LifeSciences has recently increased by 5.18%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMaravai LifeSciences does not currently pay a dividend.Dividend GrowthMaravai LifeSciences does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.15 News SentimentMaravai LifeSciences has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Maravai LifeSciences this week, compared to 2 articles on an average week.Search Interest2 people have searched for MRVI on MarketBeat in the last 30 days. MarketBeat FollowsOnly 2 people have added Maravai LifeSciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Maravai LifeSciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $126,500.00 in company stock.Percentage Held by Insiders2.49% of the stock of Maravai LifeSciences is held by insiders.Percentage Held by Institutions50.25% of the stock of Maravai LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Maravai LifeSciences' insider trading history. Receive MRVI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Maravai LifeSciences and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MRVI Stock News HeadlinesMaravai LifeSciences (NASDAQ:MRVI) Downgraded to Hold Rating by Wall Street ZenAugust 1 at 2:01 AM | americanbankingnews.comMaravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Receives $5.50 Consensus Target Price from BrokeragesJuly 28, 2026 | americanbankingnews.comThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge. Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks. Stream his free presentation to get every buy and sell recommendation with no membership or credit card required.August 3 at 1:00 AM | Chaikin Analytics (Ad)Maravai LifeSciences To Host Earnings Conference Call on Thursday, August 6, 2026July 22, 2026 | businesswire.comTriLink BioTechnologies® Further Strengthens Global IP Position with Newly Issued Patent in China for CleanCap® Capping TechnologyJuly 20, 2026 | businesswire.comThis is why Maravai Lifesciences Holdings Inc. (MRVI) is a Top penny Stock in the Top Investors PortfolioJune 7, 2026 | finance.yahoo.comMaravai LifeSciences Announces Refinancing of Credit Agreement, Extending Maturity to 2032June 3, 2026 | businesswire.comMaravai Lifesciences Shareholders Back Board, Pay, AuditorMay 29, 2026 | tipranks.comSee More Headlines MRVI Stock Analysis - Frequently Asked Questions How have MRVI shares performed this year? Maravai LifeSciences' stock was trading at $3.25 at the beginning of 2026. Since then, MRVI stock has increased by 102.2% and is now trading at $6.57. How were Maravai LifeSciences' earnings last quarter? Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) posted its quarterly earnings results on Thursday, May, 7th. The company reported $0.01 earnings per share for the quarter, beating analysts' consensus estimates of ($0.05) by $0.06. The business had revenue of $65.84 million for the quarter, compared to analyst estimates of $53 million. Maravai LifeSciences had a negative trailing twelve-month return on equity of 17.87% and a negative net margin of 51.07%. Read the conference call transcript. When did Maravai LifeSciences IPO? Maravai LifeSciences (MRVI) raised $1.5 billion in an IPO on Thursday, November 19th 2020. The company issued 60,000,000 shares at $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs served as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers. How do I buy shares of Maravai LifeSciences? Shares of MRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Maravai LifeSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Maravai LifeSciences investors own include Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), AUO (AUOTY), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings5/07/2026Today8/03/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (12m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 MRVI's financial health is in the Green zone, according to TradeSmith. MRVI has been in this zone for over 12 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Life Sciences Tools & Services Sub-IndustryLife Sciences Tools & Services Current SymbolNASDAQ:MRVI CIK1823239 Webwww.maravai.com Phone858-546-0004FaxN/AEmployees610Year Founded2014Price Target and Rating Average Price Target for Maravai LifeSciences$5.50 High Price Target$6.00 Low Price Target$5.00 Potential Upside/Downside-16.3%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($0.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$130.77 million Net Margins-51.07% Pretax Margin-92.22% Return on Equity-17.87% Return on Assets-9.08% Debt Debt-to-Equity Ratio0.72 Current Ratio5.91 Quick Ratio4.96 Sales & Book Value Annual Sales$204.73 million Price / Sales8.29 Cash Flow$0.42 per share Price / Cash Flow15.69 Book Value$1.46 per share Price / Book4.50Miscellaneous Outstanding Shares258,190,000Free Float251,761,000Market Cap$1.70 billion OptionableOptionable Beta0.65 Social Links The Infrastructure's Backbone: 10 Stocks Powering the AI BuildoutThe AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.Get This Free Report This page (NASDAQ:MRVI) was last updated on 8/3/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | SponsoredBofA: Digital Dollar Coming 2025-2030Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...Decentralized Masters | SponsoredThree oil giants buried the same discovery for 50 yearsIn 1976, Chevron tapped an energy source with no fuel costs, no carbon, and no supply chain - then killed the ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maravai LifeSciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maravai LifeSciences With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
